For patients with symptomatic disease necessitating therapy, ibrutinib is often encouraged according to four period III randomized medical trials comparing ibrutinib with chlorambucil monotherapy106 and also other frequently utilised CIT combinations, namely FCR, bendamustine plus rituximab and chlorambucil plus obinutuzumab (ClbO).107–109 Ibruti